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Natural killer (NK) cell degranulation in response
to virus-infected cells is triggered by interactions
between invariant NK cell surface receptors and
their ligands on target cells. Although HIV-1 Vpr
induces expression of ligands for NK cell activation
receptor, NKG2D, on infected cells, this is not suffi-
cient to promote lytic granule release. We show that
triggering the NK cell coactivation receptor NK-T-
and -B cell antigen (NTB-A) alongside NKG2D pro-
motes NK cell degranulation. Normally, NK cell
surface NTB-A binds to NTB-A onCD4+ T cells. How-
ever, HIV-1 Vpu downmodulates NTB-A on infected
T cells. Vpu associates with NTB-A through its trans-
membrane region without promoting NTB-A degra-
dation. Cells infected with HIV-1 Vpu mutant elicited
at least 50% more NK cells to degranulate than wild-
type virus. Moreover, NK cells have a higher capacity
to lyse HIV-infected cells with a mutant Vpu. Thus,
Vpu downmodulation of NTB-A protects the infected
cell from lysis by NK cells.
INTRODUCTION
NK cells respond to virus-infected cells without requiring prior
exposure to viral antigens. Hence, they play a major role in
managing virus-infected cells during the early stages of viral
infection before the emergence of the virus-specific adaptive
immune responses. The outcome of an NK cell response to
a target cell is determined by intracellular signaling cascades
initiated by interactions between germline encoded and invariant
receptors on the NK cell and their ligands on the target cell
(Lanier, 2005, 2008; Moretta et al., 2001; Moretta and Moretta,
2004). These receptor-ligand interactions are divided into three
major categories: inhibiting, activating, and coactivating.
One set of inhibitory receptors on NK cells (iNKR) interact with
the major histocompatibility complex class I molecules (MHC-I)Cell Host &(Ciccone et al., 1992; Dohring et al., 1996; Moretta et al., 1997;
Natarajan et al., 2002). The three major MHC-I-specific families
of iNKRs are the killer immunoglobulin (Ig)-like receptors (KIR),
whose members have varying numbers of Ig domains and ligand
specificities (recognizing HLA-A, -B or -C as ligands); the lectin-
like heterodimer of NKG2A and CD94 (recognizing HLA-E);
and interleukin-like transcript type 2 (which recognizes multiple
MHC class I molecules). Furthermore, NK cells also express
various inhibitory receptors that bind non-MHC-I ligands (re-
viewed in Borrego et al., 2002; Lanier, 2008).
While iNKR-ligand interactionsprovidea fail-safemechanismby
which NK cells avoid killing normal ‘‘self’’ cells, the lack of or
impaired expression of iNKR ligands is insufficient to trigger an
NK cell cytolytic response. The engagement of NK cell activation
receptors (aNKRs) by ligands on infected cells is required to elicit
NK cells to lyse their target cells. Triggering a variety of surface
aNKR can induce NK cell activation (reviewed in Bryceson et al.,
2006a; Lanier, 2008). The natural cytotoxicity receptors (NCRs)
containing Ig-like domains; NKp30, NKp44, and NKp46 (Pende
et al., 1999; Pessino et al., 1998); and the C-type lectin, NKG2D
(Bauer et al., 1999), are the major aNKRs. Additionally KIRs with
short intracellular tails (KIR2DS1/2 and -3, KIR3DS1) are also
aNKRs (Dohring et al., 1996; Moretta et al., 1995). Another family
of aNKRs is a lectin-like heterodimer consisting of CD94 associ-
ated with NKG2C, which binds HLA-E (Braud et al., 1998).
Although the activating NK receptors are necessary for NK-
mediated lysis of target cells, they are insufficient to induce
degranulation (Bryceson et al., 2006a) and require the concom-
itant triggering of coactivating receptors (caNKR) (Bryceson
et al., 2006a; Moretta et al., 2001). The simultaneous engage-
ment of both aNKR and caNKR by their ligands on target cells
prompts resting NK cells to release their lytic granules (Bryceson
et al., 2006b, 2009).
Earlier studies indicated that NK cells are ineffective at killing
autologous, primary HIV-1-infected T cells (Bonaparte and
Barker, 2003; Ruscetti et al., 1986; Zheng and Zucker-Franklin,
1992). However, examination of the infected cell surface re-
vealed that virus infection leads to a decrease in surface expres-
sion of HLA-A and -B (Bonaparte and Barker, 2004) through the
action of Nef (Cohen et al., 1999) and an increase in ligands for
NKG2D (Ward et al., 2007) through the action of Vpr proteinMicrobe 8, 397–409, November 18, 2010 ª2010 Elsevier Inc. 397
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inhibitory ligands combined with the upregulation of activating
ligands should lead one to predict that HIV-1-infected cells could
serve as ideal targets for NK cell-mediated destruction. How-
ever, the ability of NK cells from even healthy uninfected individ-
uals to destroy HIV-1-infected cells has been consistently char-
acterized to be weak at best (Bonaparte and Barker, 2003; Fogli
et al., 2008; Ruscetti et al., 1986; Tomescu et al., 2007; Ward
et al., 2007; Zheng and Zucker-Franklin, 1992). Therefore, addi-
tional factors must be involved in regulating NK activity in the
presence of HIV-1 infection. One such factor that regulates NK
cell cytolytic activity is NTB-A. NTB-A is found on all blood-
derived NK, T, and B cells and is a member of the signaling
lymphocytic activation molecule (SLAM) family of receptors
(Bottino et al., 2001). It contains immunoreceptor tyrosine-based
switchmotifs that are docking sites for the SH2 domain of SLAM-
associated proteins and the related Ewing’s sarcoma-associ-
ated transcripts (EAT)-2 (Bottino et al., 2001; Falco et al., 2004;
Flaig et al., 2004). NTB-A is a type I transmembrane protein of
the Ig superfamily with an N-terminal IgV domain and a proximal
truncated C-terminal IgC2 domain (Bottino et al., 2001). NTB-A
functions as a homotypic ligand-caNKR pair (Falco et al., 2004;
Flaig et al., 2004) and has been observed to induce NK cell cyto-
toxicity (Bottino et al., 2001; Flaig et al., 2004). Moreover, we
have demonstrated that NTB-A facilitates NK cell-mediated
killing of HIV-1-infected cells (Ward et al., 2007). However,
HIV-1 downmodulates NTB-A on the infected cell surface (Fogli
et al., 2008; Ward et al., 2007). The consequence that decreased
NTB-A expression on HIV-1-infected cells will have on the ability
of NK cells to lyse the infected target remains to be determined.
RESULTS
Despite NTB-A Surface Downmodulation, HIV-1
Does Not Alter the Steady-State Levels of NTB-A
It is unclear if the surface downregulation ofNTB-AbyHIV-1 coin-
cides with changes in the total NTB-A levels of the infected cell.
We addressed this question by comparing the levels of NTB-A,
after staining the surface of HIV-infected cells with anti-NTB-A,
with the levels of NTB-A, after permeabilizing the infected cells
and then staining them with anti-NTB-A. As a positive control,
we evaluated CD4 expression, on and within infected cells. We
observed that cell surfaceNTB-Aexpressionwas reducedduring
infection, but total NTB-A levels remained unchanged (Figures
1A). In contrast, HIV-1 infection of primary CD4 T cells led to
a decrease in both cell surface and intracellular CD4 expression
(Figures 1A). This indicated that, unlike CD4, downregulation of
NTB-A on the surface by HIV-1 does not coincide with changes
in the steady-state levels of NTB-A in the infected cells.
NTB-A Is Downregulated by HIV-1 Vpu
Since the HIV-1 accessory proteins, Nef and Vpu, induce cell
surface downregulation of a number of host cell proteins (Garcia
and Miller, 1991; Kerkau et al., 1997; Moll et al., 2010; Neil et al.,
2008; Schwartz et al., 1996; Van Damme et al., 2008;Willey et al.,
1992), we askedwhether either or both of the viral gene products
may play a role in NTB-A downregulation. We found that HIV-
1DNef downregulated NTB-A from the infected cell surface to
the same extent (MFI = 461 compared with MFI = 2088 for unin-398 Cell Host & Microbe 8, 397–409, November 18, 2010 ª2010 Elsefected cells) (Figure 1B) as wild-type (WT) HIV-1 (MFI = 485
compared with MFI = 2032 for uninfected cells) (Figure 1B). In
contrast, HIV-1DVpu was unable to downregulate NTB-A (MFI =
1998 compared with MFI = 2055 for uninfected cells) (Figure 1B).
To determine whether Vpu is sufficient to downregulate cell
surface NTB-A, we determined cell surface NTB-A expression
on both Vpu-transduced and untransduced cells. As a positive
control, we also evaluated the cell surface expression of CD4.
As expected, cell surface CD4 expression was downmodulated
on Vpu-transduced cells (MFI = 1427) relative to CD4 on untrans-
duced cells (MFI = 6094) (Figure 1C). We found NTB-A to be
downmodulated on Vpu-expressing cells (MFI = 1485), relative
to NTB-A on untransduced cells (MFI = 2962) (Figure 1C). These
experiments indicate that Vpu is both necessary and sufficient
to downregulate NTB-A.
NTB-A Downregulation by Vpu Is Mechanistically
Distinct from that of CD4 and BST-2 Downregulation
Vpu enhances virus production by downmodulating CD4 and
bone marrow stromal antigen 2 (BST-2) expression. Vpu serves
as an adaptor protein linking CD4 and BST-2 to b-TrCP, a human
F box protein that functions as a substrate recognition receptor
for the multisubunit E3 ubiquitin ligase (Douglas et al., 2010;
Margottin et al., 1998). To determine whether b-TrCP association
with Vpu is required for NTB-A downmodulation, we asked if Vpu
with both serine residues mutated to asparagines (Vpu [S52,
56N]) would be able to downmodulate NTB-A. As expected,
Vpu (S52, 56N), failed to downregulate CD4 as compared to
WT Vpu (Figure 2A). In contrast, we found that Vpu (S52, 56N)
was able to downregulate NTB-A to comparable levels as WT
Vpu (Figure 2A). Our studies therefore illustrate that Vpu downre-
gulates cell surface NTB-A by a mechanism that is distinct from
that of CD4 and BST-2 downregulation.
To rule out any role of the putative ubiquitination residues in
the cytoplasmic tail of NTB-A on Vpu’s ability to downmodulate
NTB-A, we generated a mutant of NTB-A lacking a cytoplasmic
tail (NTBA D250–331). Following transfection with Vpu, we found
that removal of the cytoplasmic tail did not significantly alter the
capacity of Vpu to downmodulate NTB-A (Figure 2B).
Because proteasomal degradation has been implicated in
CD4 or BST-2 downmodulation (Douglas et al., 2010; Margottin
et al., 1998), we asked what effect proteasomal inhibition would
have on surface expression of NTB-A. As expected (Schubert
et al., 1998), treatment with 100 nM epoxomicin or 10 mM MG-
132 abrogated the capacity of Vpu to downregulate CD4 surface
expression when compared to that in cells treated with vehicle
only (Figure 2C). In contrast, treatment of NTB-A expressing cells
with proteasome inhibitors failed to relieve NTB-A downregula-
tion by Vpu relative to vehicle-treated cells (Figure 2C). Thus,
Vpu-mediated NTB-A downregulation is independent of protea-
some activity.
Vpu Does Not Increase NTB-A Endocytosis
or Degradation within Acidified Vesicles
In the study shown in Figure 1, we demonstrated that Vpu did not
change the steady-state levels of NTB-A even though surface
levels of NTB-A were decreased. For this reason, we wanted
to determine if Vpu was increasing internalization of NTB-A
from the cell surface. As Figure 3A shows, NTB-A wasvier Inc.
Figure 1. Cell Surface but Not Total NTB-A Expression Is Reduced by HIV-1-Vpu
(A) CD4+ T cells were infected with DHIV-3 and were stained for surface (i and iii) or permeabilized and evaluated for total NTB-A or CD4 (ii and iv). Uninfected cells
were used as a control. All samples were stained intracellularly for HIV-1 p24 antigen. A comparison of HIV-1 p24+ (blue line), HIV-1 p24 (red line), and uninfected
cells (black line) is presented. This figure is representative of two separate studies.
(B) (i) DHIV-3WT, (ii) DHIV-3DNef, and (iii) DHIV-3DVpu-infected primary T cell blasts were surface stained for NTB-A and then stained intracellularly for HIV-1 p24
Ag. Histograms were derived following acquisition on a flow cytometer of either 104 viable HIV-1 p24 cells (for uninfected cells, red line) or 104 viable HIV-1 p24
Ag+-infected cells (blue line).
(C) Primary CD4 T cell blasts were transduced with a retroviral vector expressing Vpu-GFP (blue line) or GFP (red line). Untransduced cells are shown in black.
Following transduction, cells were stained with anti-CD4 (i) or anti-NTB-A (ii). Histograms were derived following acquisition on a flow cytometer of 104 viable and
GFP+ cells. For untransduced cells, 104 viable cells were collected. The figure is representative of three separate experiments.
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less if Vpu was present or not.
Acidification of endocytic vesicles is a necessary step in
various processes following endocytosis, including receptorCell Host &recycling (Tycko et al., 1983). Bafilomycin A1 inhibited the
capacity of Vpu to downregulate BST-2 from the cell surface
and enhanced intracellular BST-2 levels by either blocking
pH-dependent trafficking to late endosomes or inhibitingMicrobe 8, 397–409, November 18, 2010 ª2010 Elsevier Inc. 399
Figure 2. NTB-A Downmodulation by Vpu Does Not Involve Ubiquitination
(A) HeLa cells expressing CD4 orNTB-Awere transfectedwithGFP (i and iv), Vpu-GFP (ii and v), or Vpu(S52,56N)-GFP (iii and vi). Transfected cells were evaluated
for CD4 (i–iii) or NTB-A (iv–vi).
(B) HeLa cells expressing NTB-A or NTB-A D250–331 were transfected with GFP (i and ii) or Vpu-GFP (iii and iv) and evaluated for NTB-A.
(C) HeLa cells expressing CD4 (i–iii) or NTB-A (iv–vi) cells were transfected with Vpu-GFP before treatment with DMSO, epoxomicin, or MG-132. Transfected cells
were evaluated for CD4 (i–iii) or NTB-A (iv–vi).
Cell Host & Microbe
Vpu Downmodulates NTB-A to Evade NK Cell Lysislysosomal degradation (Mitchell et al., 2009). We treated HeLa-
NTB-A cells with 100 nM bafilomycin A1 and found no effect on
Vpu’s ability to modulate NTB-A (Figure 3B). The MFI of NTB-A
on Vpu-transfected cells was 5,309 compared with an MFI of
22,578 for NTB-A on untransfected cells. The MFI for NTB-A400 Cell Host & Microbe 8, 397–409, November 18, 2010 ª2010 Elseon Vpu-transfected cells treated with 100 nM bafilomycin was
5,121 compared with 23,143 for bafilomycin A1-treated un-
transfected cells. This same concentration of bafilomycin A1
prevented Nef-dependent downmodulation of CD4 (see Fig-
ure S1 available online).vier Inc.
Figure 3. Vpu Does Not Increase NTB-A’s Endocytosis or Lead to Its Degradation in Acidified Vesicles
(A) HeLa-NTB-A cells transfected with either GFP or Vpu-GFPwere surface stained with unconjugated anti-human NTB-A. At 0, 5, 10, 15, 30, and 45min post-Ab
incubation at 37C, and then fixed and stained with an APC-conjugated secondary antibody. At least 104 GFP (red) and Vpu-GFP (blue) expressing viable cells
were collected by flow cytometry.
(B) HeLa-NTB-A cells were transfected with either GFP (i and iii) or Vpu-GFP (ii and iv) before treatment with either DMSO or bafilomycin A1. Transfected cells
were evaluated for NTB-A. At least 104 GFP (red) and 104 GFP+ (blue) viable cells were collected by flow cytometry. Results are representative of five different
experiments.
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for NTB-A Downregulation
Although NTB-A downregulation by Vpu is mechanistically
distinct from that of CD4 and BST-2, it remains to be determined
if Vpu binds to NTB-A as it does to CD4 or BST-2. To evaluate
this, we first asked if NTB-A binds directly to Vpu. As shown in
Figure 4A, we observed a 37 kD band corresponding to Vpu-GFPCell Host &only in the lane corresponding to NTB-A expressing cells
transfected with Vpu; all other lanes did not contain this band.
Taken together, the above findings indicated that Vpu binds
to NTB-A.
Since Vpu binds to NTB-A, we proceeded to determine the
region of Vpu that was critical for its interaction with NTB-A.
Vpu-mediated downregulation of BST-2 points to Vpu’sMicrobe 8, 397–409, November 18, 2010 ª2010 Elsevier Inc. 401
Figure 4. Vpu Binds to NTB-A through Its
Transmembrane Region
(A) HeLa and HeLa-HA-NTB-A cells were trans-
fected with GFP or GFP-Vpu. As a control,
untransfected cells were used. The cells were
lysed and immunoprecipitated using anti-HA Ab.
Lysates were analyzed by western blot for b-actin
(42 kDa) by loading 20 mg of lysate per sample.
Immunoprecipitates were analyzed by western
blot for NTB-A (60 kDa) and Vpu-GFP (37 kDa)
using antibodies directed to NTB-A and Vpu.
(B) HeLa-HA-NTBA cells were transfected with
GFP, Vpu-GFP, and URD-GFP. Lysates were
analyzed by western blot and probed for Vpu
and b-actin. Immunoprecipitates were analyzed
by western blot and probed for NTB-A and Vpu.
(C) CD4+ T cell blasts were infected (blue line) with
either Vpu transmembrane domain mutant encod-
ing HIV-1NL4/3 (URD) (i and iii) or WT HIV-1NL4/3
(ii and iv) at an moi of 0.01. Infected cells were
stained with anti-NTB-A (i and ii) or anti-CD4
(iii and iv). As a control, uninfected cells (red)
were also stained with anti-NTB-A or anti-CD4.
HIV-1 p24 is represented in red, and HIV-1 p24+
is represented in blue. Results are representative
of three different experiments.
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dulation (Van Damme et al., 2008). To determine if Vpu inter-
acted with NTB-A through the transmembrane region, we
utilized a Vpu mutant that encodes a scrambled amino acid
sequence of the transmembrane domain (URD) (Schubert
et al., 1996). We immunoprecepitated NTB-A from lysates of
NTB-A transfected with Vpu-GFP or URD-GFP followed by
immunoblotting with anti-Vpu. As controls, we probed the
input lysates with anti-Vpu and anti-b-actin and probed the
IP with anti-NTB-A. Figure 4B illustrates that NTB-A does not402 Cell Host & Microbe 8, 397–409, November 18, 2010 ª2010 ElseW
la
d
N
W
S
d
in
tivier Inc.interact with the transmembrane scram-
bled Vpu mutant URD but does bind to
the WT Vpu. Vpu used in our study is
part of a GFP fusion protein. Hence, it
may be possible that detection of Vpu
when immnoprecipitating NTB-A could
be due to the GFP binding to NTB-A.
However, this does not appear to be
the case, since URD-GFP did not bind
to NTB-A even though the Vpu Ab
used in our study detected URD-GFP in
the lysates. Thus, Vpu interacts with
NTB-A through the transmembrane por-
tion of Vpu.
Next we infected primary CD4 T cells
with HIV-1NL4/3 and HIV-1NL4/3-URD. As
shown in Figure 4C, we found that
URD-infected cells expressed NTB-A on
primary T cells to a similar extent as that
on uninfected cells (MFI of 8960 for HIV-
infected cells and 7313 for uninfected
cells). However, URD downregulated
CD4 indistinguishably from WT Vpu. OnT-Vpu-infected cells, both NTB-A and CD4 are downregu-
ted. Thus the transmembrane portion of Vpu is critical for
ownmodulation of NTB-A but not of CD4.
TB-A Is Required for NK Cells to Degranulate
hen the Activation Receptor NKG2D Is Triggered
ince NTB-A was downregulated by Vpu, we next wanted to
etermine the consequences modulating this ligand on the
fected cells surface had on the NK cells’ cytolytic func-
on. To begin, we asked whether NTB-A engagement, in the
Figure 5. NTBA Is Involved in NK Cell
Degranulation When NKG2D Is Also Trig-
gered
(A) Freshly isolated human PBMCs were labeled
with antibodies specific for NK cells (CD56) and
the degranulation marker, CD107a, after a 4 hr
exposure to P815 cells with either (i) nonspecific
Ab, (ii) anti-NKG2D, (iii) anti-NTB-A, and (iv) anti-
NKG2D and anti-NTB-A. T cells, NKTs, B cells,
and macrophages/monocytes were excluded by
staining with anti-CD3, -CD20, and -CD14. NK
cells were detected by CD56 in the CD3-, CD20-,
and CD14-negative population. Numbers repre-
sent the percentage of cells in that quadrant, and
numbers in parentheses represent the percentage
of NK cells that express CD107a. Results are
representative of three separate studies.
(B) Freshly isolated human peripheral blood
mononuclear cells (PBMCs) were incubated
alone (i and v) or together with either uninfected
autologous CD4 T cells (ii and vi); K562 cells
(iii and vii); or purified, VSV-G-pseudotyped
DHIV-3 WT (infected at an moi of 5) autologous
T cells (iv and viii). Following the coincubation the
cells were stained with fluorochrome-conjugated
CD69 or CD107a. T cell, B cells, NKT, and macro-
phages/monocytes were excluded by staining
for CD3, CD20, and CD14 with fluorochrome-
conjugated Ab and gating on the negative cells
for NK cells. NK cells were identified following
staining with anti-CD56. Numbers in dot plots
represent percentage of CD69+ CD56+ cells (i–iv)
or CD107a+ CD56+ cells (v–viii). In a similar exper-
iment, the percentage of NK cells expressing
both CD69 and CD107a was determined after
exposure to (ix) K562 cells or (x) purified DHIV-3
WT-infected autologous T cells. Numbers in (ix)
and (x) represent the percentage of cells within
the quadrant, and number in parentheses repre-
sent the percentage of CD69+ NK cells that
are either CD107a or CD107a+. Twenty-thou-
sand viable cells were collected per sample.
Results are representative of three different
experiments.
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degranulate.
Ligands for the activation receptor NKG2D, such as ULBP-1
and -2, are able to trigger NK cell lysis of HIV-infected cells
(Ward et al., 2007). However, it has also been demonstrated
that triggering NKG2D alone on primary NK cells is insufficient
to induce optimal degranulation (Bryceson et al., 2006b).
Whether NTB-A is required for triggering NK cell degranulationCell Host & Microbe 8, 397–409, Nwhen NKG2D is also triggered remains
to be determined. To address this issue,
we utilized a redirected degranulation
assay in which only these two specific
receptors can be triggered using ago-
nist antibodies as ligand mimics. We
found that very few (1.6%) fresh blood
derived-NK cells spontaneously express
CD107a (Figure 5Ai). When NKG2D wastriggered alone, only 1.3% of NK cells degranulated (Figure 5Aii).
Similarly, engagement of NTB-A alone caused only 1.8% of NK
cells to express CD107a (Figure 5Aiii). However, when NKG2D
andNTB-Awere triggered together, the percent of degranulating
NK cells increased to 19.3% (Figure 5Aiv). These results demon-
strate that triggering NTB-A together with NKG2D induces the
release of granules from NK cells even though triggering either
receptor alone has a minimal effect.ovember 18, 2010 ª2010 Elsevier Inc. 403
Figure 6. Vpu’s Downmodulation of NTB-A Prevents NK Cell Degranulation and Lysis of HIV-Infected Cells
(A) Peripheral blood NK cells were incubated at a effector cell to target cell ratio of 1:2 with (i) no targets, (ii) K562 cells, (iii) uninfected CD4 primary T cells, (iv)
HIV-1 (DHIV-3) WT-infected primary T cells, or (v) HIV-1 (DHIV-3)-infected primary T cells expressing Vpu in which the amino acid sequence in the
transmembrane region is scrambled (URD). Cells were incubated in the presence of anti-CD107a for 4 hr. Twenty-thousand NK cells (CD56
+CD3) were
collected per sample and further analyzed for expression of CD107a, CD159a (HLA-E-specific iNKRs), and CD158a and CD158b (HLA-C-specific
iNKRs). Numbers in quadrant 2 are the percent of NK cells possessing inhibitory receptors to HLA-C and -E that express CD107a. Numbers in
quadrant 4 are the percent of NK cells lacking inhibitory receptors to HLA-C and -E that express CD107a. Results are representative of three different
experiments.
(B) Peripheral blood NK cells were stimulated overnight with 200 U/mL rhIL-2 and then were incubated with the same targets as well as stained and analyzed in
a similar fashion as in Figure 6A. Results are representative of three different experiments.
(C) Peripheral blood NK cells were incubated at an effector cell to target cell ratio of 1:2 for 4 hr without targets, or with K562, uninfected CD4+ T cells,
DHIV-3 WT-infected cells, or DHIV-3-URD infected cells. One group of NK cells were pretreated with anti-NTB-A blocking antibody (ON56) for 20 min prior
to exposure to DHIV-3 URD infected cells and stained for CD107a expression. Twenty-thousand NK cells (CD56
+CD3) were collected for each group. This
is a representative of two separate studies.
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Vpu Downmodulates NTB-A to Evade NK Cell LysisHIV-1-Infected Cells Induce Vigorous Activation of NK
Cells but Fail to Trigger Maximal Degranulation
Our previous studies demonstrated that HIV-1-infected cells
have a modest sensitivity to lysis by NK cells (Bonaparte and
Barker, 2004; Fogli et al., 2008; Ward et al., 2007). Given that
NTB-A is required as a costimulatory signal to trigger NK cells
to degranulate (Figure 5A), and that NTB-A is downmodulated
by Vpu (Figures 1B and 1C), we wished to determine whether
the failure of NK cells to lyse infected cells effectively occurs at
the level of degranulation per se or at the prior step of activation.
For this purpose we evaluated the proportion of NK cells ex-
pressing on their surface the activation marker, CD69 (Ziegler
et al., 1994), and the degranulation marker, CD107a (Peters
et al., 1991), after a 4 hr exposure to HIV-infected cells (Fig-
ure 5B). As a positive control target cell, we utilized the NK-sensi-
tive cell line, K562 cells, and as a negative control, uninfected
CD4 T cells.
Very few NK cells expressed CD69 or CD107a spontaneously
(1.2% and 1.0%, respectively) when freshly isolated from the
blood (Figures 5Bi and 5Bv). Following exposure to uninfected
CD4 T cells, 7.6% of NK cells expressed CD69 and 6.3% of
NK cells expressed CD107a (Figures 5Bii and 5Bvi). When
exposed to K562 cells, 34.8% of NK cells expressed CD69
and 35.2% expressed CD107a (Figures 5Biii and 5Bvii), indi-
cating vigorous activation and degranulation. When exposed to
HIV-1-infected cells, 43.2% of NK cells expressed CD69 (Fig-
ure 5Biv), indicating potent activation; however, only 11.6% of
the cells expressed the degranulation marker CD107a (Fig-
ure 5Bviii). Therefore, we concluded that the failure of NK cells
to lyse HIV-1-infected target cells occurs at or near the stage
of degranulation, but not at an earlier activation step.
The results in Figures 5Bi–5Bviii were confirmed on a per-cell
basis by comparing NK cell activation and degranulation simul-
taneously. We found that 66% of the CD69+ NK cells degranu-
lated in response to K562 cells (Figure 5Bix). In contrast, only
19% of CD69+ NK cells degranulated in response to HIV-1-in-
fected T cells (Figure 5Bx). Our observations demonstrate that
NK cells become activated in response to HIV-1-infected
T cells but fail to degranulate to the same extent.
Vpu’s Downmodulation of NTB-A Is Responsible
for Preventing NK Cells from Degranulating and Lysing
HIV-Infected Cells
Since Vpu downmodulates NTB-A (Figure 1), and NTB-A is
required for NK cells to degranulate when NKG2D is triggered
(Figure 5), we predicted that introducing the URD mutation in
HIV-1 Vpu, which fails to downregulate NTB-A (Figure 4), would
enable NK cells to degranulate in response to HIV-1-infected
cells. As controls, we evaluated the percentages of NK cells
degranulating when cultured alone, with uninfected CD4
T cells, with K562 cells, and with CD4 T cells infected with
HIV-1 WT. As shown in Figure 6A, regardless of the iNKRs ex-
pressed, NK cells degranulated 3-fold higher against URD-in-
fected cells (63.34% of total NK cells evaluated were CD107a+)(D) NK cells purified from whole blood were left unstimulated or treated overnigh
uninfected CD4+ T cells, DHIV-3 WT-infected cells, or DHIV-3-URD-infected cells
ation (SD) is shown for each group. All groups were done in triplicate. This is repr
the mean percent specific lysis.
Cell Host &than against WT infected cells (22.6% of total NK cells evaluated
were CD107a+). Of the NK cells exposed to K562 cells, 71.85%
of the cells degranulated. Less than 7%of NK cells degranulated
when exposed to uninfected CD4+ T cells.
Since HLA-C and -E remain on the infected cell surface and
may suppress NK cell response to the infected cells (Bonaparte
and Barker, 2004; Cohen et al., 1999), we analyzed the capability
of NK cells lacking iNKRs to HLA-C and -E to degranulate.
We have also performed analysis with NKG2A+ (CD159a, part
of the HLA-E-specific receptor) as well as KIR2DL1 and 2/3+
(CD158a and -b, two HLA-C-specific receptors) CD56+ CD3
cells. This is important since NK cells are variegated with regards
to expression of these receptors (Bonaparte and Barker, 2004).
As seen in Figure 6A, only 1.3% percent of fresh NK cells lacking
HLA-C and -E iNKRs degranulate, and similarly, when exposed
to uninfected CD4 T cells, 4.89% of NK cells degranulated.
When exposed to K562 cells, 34.30% of NK cells degranulated.
However, when exposed to HIV-1WT 15.21% of NK cells degra-
nulated. Over twice as many NK cells degranulated (39.89%)
when exposed to HIV-1 URD-infected cells. Thus, Vpu’s ability
to downmodulate NTB-A limits the capacity of NK cells to degra-
nulate by at least 2-fold. Although the HLA-C and -E on infected
cells decreased NK cell degranulation by 2-fold, Vpu prevented
NK cells expressing iNKRs to HLA-C and -E from lysing infected
cells by 2-fold (Figure 6A).
Studies by Drs. Bryceson and Long (Bryceson et al., 2005,
2006b, 2009) indicated that ‘‘resting’’ NK cells required engage-
ment of two activation receptors in order to degranulate. There-
fore we asked whether stimulation of NK cells with IL-2 prior to
exposure to target cells would still require that two activation
receptors be engaged to get maximal degranulation. Stimulation
with IL-2 leads NK cells to express the activation marker CD69
(see Figure S2) regardless of target cells used to stimulate
the NK cells. When exposed to 200 U/ml of IL-2, overall, NK
cells degranulated to a greater extent than NK cells not exposed
to cytokines (Figure 6B), even though the pattern of degranula-
tion remained similar. Thus even ‘‘activated’’ NK cells require
engagement of two activation receptors in order to achieve
maximal degranulation.
Next we wanted to determine whether the URD-infected cells
triggered NK cell degranulation to a greater extent because of
its inability to downmodulate NTB-A. To accomplish this, we
blocked the NTB-A on the NK cells with anti-NTB-A antibodies
prior to adding URD-infected T cells. As seen in Figure 6C, NK
cells had a decreased ability to degranulate when exposed to
URD cells after they were treated with anti-NTB-A blocking Ab
prior to adding the target cells (Figure 6C).
Since degranulation of NK cells equates to its capacity to lyse
target cells (Alter et al., 2004), we wanted to determine if Vpu’s
ability to downmodulate NTB-A decreased the responding NK
cells’ ability to lyse the infected cells. In Figure 6D, NK cells
had a 2-fold greater capacity to lyse HIV-infected cells with
URD compared to target cells infected with WT virus (p < 0.05
for both E:T ratios; Student’s t test). The level of lysis seent with 200 U/mL rhIL-2 and then used in a 51Cr release assay with K562 cells,
at E:T ratios of 2.5:1 and 5:1. Mean percent specific lysis ± the standard devi-
esentative of two separate studies. Error bars represent standard deviation of
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Figure 7. Model of Vpu Modulation of NTB-
A in the Context of Vpr and Nef and Their
Impact on NK Cell Lytic Response to HIV-
Infected Cells
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cells to lyse the NK-sensitive K562 cell line (Figure 6D) (p > 0.1
for both E:T ratios; Student’s t test). Thus, these studies indicate
that Vpu’s ability to prevent NTB-A downmodulation protects
the infected cell from lysis by NK cells.
DISCUSSION
We had previously demonstrated the importance of NKG2D and
NTB-A, separately, in the destruction of HIV-infected cells by NK
cells (Ward et al., 2007). However, the connection between these
receptors in the NK cell cytolytic response has never beenmade.
Moreover, it has never been reported that NTB-A is capable of
triggering degranulation in combination with NKG2D engage-
ment. This is important to know, since the proper activating
receptor pairings are essential for NK cells to degranulate (Bry-
ceson et al., 2006b), and here we begin to evaluate which activa-
tion/coactivation receptor pairs may be functional against HIV-1-
infected cells. In this study, we demonstrate that simultaneous
engagement of NKG2D and NTB-A is essential to elicit NK cell
degranulation. This is not only true of ‘‘resting’’ NK cells but of
activated ones as well. In contrast, triggering NKG2D and the
activation coreceptor DNAM-1 simultaneously was insufficient
to induce degranulation even after exposure of NK cells to cyto-
kines (data not shown). This is important since HIV-infected cells
express CD155, the ligand for DNAM-1 (Z.B.D. and E.B., unpub-
lished data).
By downregulating NTB-A, Vpu may protect HIV-1-infected
cells from NK killing. We have noted that the URD-infected cells
were lysed by NK cells 2-fold higher than lysis of HIV-1-infected
cells expressingWT Vpu. Furthermore, the level of lysis of URD-in-
fectedcells approached the level ofNKcell lysis ofK562cells. This
was important to note, since K562 cells are sensitive to NK cell-
mediated lysis. It is noteworthy that HIV-2 does not encode
a Vpuprotein (Bour andStrebel, 1996) even though it does encode406 Cell Host & Microbe 8, 397–409, November 18, 2010 ª2010 Elsevier Inc.Vpr and Nef, and furthermore, we have
found that HIV-2-infected cells do not
downregulate NTB-A and are killed more
efficiently by NK cells than HIV-1-infected
cells (J.P.W. and E.B., unpublished data).
One of the earliest observations
regarding HIV-1 evasion of NK cell
responses made by Drs. David Balti-
more’s and Jack Strominger’s laborato-
ries over 10 years ago was that HIV-1
Nef downmodulated HLA-A and -B but
left -C and -E on the infected cell surface
(Cohen et al., 1999). The latter two HLA-
class I molecules were believed to
prevent NK cell killing of HIV-infected
cells (Cohen et al., 1999). However, we
have found that NK cells are variegatedwith regards to expression of HLA-C and -E iNKRs, and a signif-
icant number of NK cells could not be controlled by HLA-C or
-E (Bonaparte and Barker, 2004). In fact, we found that NK cells
lacking HLA-C and -E iNKRs lysed HIV-infected cells, though
modestly, relative to the ability of the NK cells to lyse the NK-
sensitive cell line, K562 cells (Bonaparte and Barker, 2004). In
the present study, we demonstrate that HLA-C and -E control
NK cells ability to degranulate. Although they reduce the ability
of NK cells to release lytic granules by 2-fold, they still do not
prevent degranulation entirely. Moreover, our current study
shows that Vpu’s impact on the ability of NK cells to degranu-
late appears to be far greater than HLA-C and -E.
Although our studies centered specifically on Vpu derived
from HIV-1NL4/3, we have observed NTB-A downmodulation on
cells infected with other strains such as HIV-1SF162 and HIV-
1SF128A (Ward et al., 2007). Moreover, we have even observed
downmodulation of NTB-A on infected cells derived from HIV-
1-infected patients (Fogli et al., 2008).
NTB-A downmodulation by Vpu reveals a similarity with Vpu-
mediated downmodulation of BST-2 (Neil et al., 2008; Van
Damme et al., 2008), in that the transmembrane region of Vpu
is important for not only BST-2 downmodulation (Van Damme
et al., 2008) but also for NTB-A downmodulation. However, aside
from this similarity in Vpu-mediated downmodulation of BST-2
and NTB-A, there are a couple of notable differences. First,
downmodulation of NTB-A does not require the phosphorylation
of serines in the 52nd and 56th positions of Vpu while it appears
to be required for BST-2/tethein downmodulation (Mitchell et al.,
2009). Second, Vpu-mediated downmodulation of BST-2 is sen-
sitive to proteasome inhibitors and inhibitors of endosomal/lyso-
somal acidification (bafilomycin A1) (Mitchell et al., 2009), but
Vpu-mediated downmodulation of NTB-A is not.
From our studies a model is generated showing the steps
leading to NK cells’ response to HIV-infected cells and how the
HIV-infected cell evades lysis (see Figure 7). Following HIV entry,
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the virus begins to express one of the early gene products, Nef.
This viral protein downmodulates HLA-A and -B. While the
decrease of the two MHC class I molecules lowers the capacity
of HLA-A and -B restricted HIV-1 peptide antigen specific cyto-
toxic T-lymphocytes from lysing the infected cells (Collins et al.,
1998), they also reduce the threshold for inhibiting KIR3DL1-
bearing NK cells. Another HIV-1 gene product, Vpr, enhances
HIV virion production through its ability to activate ATR.
However, the activation of ATR also led to the expression of
NKG2D ligands (i.e., ULBP-1 and -2) on the infected cells.
Thus, the combination of Vpr and Nef activities should increase
the susceptibility of infected cells to lysis by NK cells. Although
HLA-C and -E remain on the infected cells surface, they only
affect a subpopulation of NK cells. However, the downmodula-
tion of NTB-A on the infected cell decreases NK cells’ ability to
degranulate even though NKG2D ligands are present and HLA-
A and -B are downmodulated. Without engaging NTB-A on NK
cells, triggering NKG2D is insufficient for NK cells to degranulate.
Thus, despite the activation of NK cells by HIV-infected cells, the
lysis of the target cell does not occur because Vpu prevents
the release of lytic granules by NK cells by downmodulating
the ligand to NTB-A responsible for the second signal needed
for degranulation (Bryceson et al., 2006b).
EXPERIMENTAL PROCEDURES
Primary Cells and Cell Lines
All primary cells used in this study were isolated from peripheral blood ob-
tained from healthy HIV-1 uninfected donors after informed written consent
was acquired in accordance with the Declaration of Helsinki and the policies
of the Institutional Review Board at Rush University Medical Center, Chicago,
IL, USA. CD4 T cells were isolated and stimulated in vitro as described (Ward
et al., 2009). The 293 FT cell line was used in the generation of viruses
and vectors and maintained according to the manufacturer’s (Invitrogen)
specifications. K562 cells, P815 cells, and HeLa and Jurkat E6-1 cell
lines were obtained from ATCC and maintained according to distributors’
recommendations. HeLa-CD4 cells were obtained from Dr. Richard Axel
(Columbia University, NY, USA) through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH (HeLa-T4+) and maintained
in medium containing 500 mg/ml G418 (Invitrogen). HeLa-NTBA and HeLa-
NTBAD250–331 cells were generated by transduction of HeLa cells with retro-
viral particles encoding a bicistronicmRNA for NTB-A or NTB-AD250–331 and
puromycin resistance. Stably transduced cells were selected in 300 ng/ml
puromycin (Invitrogen) for 60 days and subjected to three rounds of cell sorting
(FACS Aria; BDIS) for cell surface NTB-A expression. Sorted cells were main-
tained in medium containing 200 ng/ml puromycin.
Antibodies
Pacific Blue-conjugated anti-CD3, -CD20, -CD14, and -CD4; FITC-conjugated
anti-CD69; and PE-conjugated anti-CD107a and staining controls were ob-
tained from BD PharMingen. APC-conjugated anti-NTBA was obtained from
R&D Systems. AF700-conjugated anti-CD56 and PECy7 anti-CD16 were ob-
tained from Biolegend. FITC- and PE-conjugated anti-HIV-1 p24 was obtained
fromBeckman Coulter. Purified anti-NKG2D (BD PharMingen) and anti-NTB-A
(R&D Systems) were used in the redirected degranulation assay. HIV-1NL4-3
Vpu antiserum was obtained from Dr. Frank Maldarelli and Dr. Klaus Strebel
(NCI, NIH) through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH. HRP-conjugated mouse anti-rabbit, rabbit anti-
goat, and donkey anti-mouse antibodies were obtained from Jackson
Immunoresearch.
Simultaneous detection of surface antigens and intracellular HIV-1 p24
antigen (Ag) was done as previously described (Ward et al., 2009). For GFP-ex-
pressing cells or for HeLa-NTBA cell sorting, only surface antigen staining wasCell Host &performed. For determination of total NTB-A or CD4 cellular content, simulta-
neous cell surface and intracellular labeling was performed with the same anti-
body. Samples were acquired using FACS LSRII. Analysis of flow cytometric
data was performed with FloJo Software (TreeStar, Inc).
Viruses and Vectors
To eliminate possible differences in replication kinetics due to the presence or
absence of Vpu andNef in the studies described in Figures 1, 5, and 6, we used
a defective HIV-1 construct, DHIV-3, that has a deletion in the env gene. We
then provided the VSV-G glycoprotein in trans to form pseudotyped virions
as described (Andersen et al., 2006; Bosque and Planelles, 2009). The
HIV-1NL4/3 reagent was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH; HIV-1NL4/3-URD was a direct
gift of Dr. Klaus Strebel, NIH. Viral particles were produced and titered as previ-
ously described (Ward et al., 2009).
Human codon-optimized Vpu sequence of HIV-1NL4/3 (pcDNA-hVpu) was
obtained through the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH; pcDNA-hVpu was from Dr. Stephan Bour and
Dr. Klaus Strebel (NIH). The human codon-optimized Vpu sequence was
PCR amplified with appropriate restriction enzyme extensions and cloned
into pAcGFP-N1 (Clontech) to generate Vpu with a C-terminal GFP fusion
protein. The vector pAcGFP-Vpu S52,56N was constructed by site-directed
mutagenesis (Stratagene) using the primer pair shown in Figure S3A. The
Vpu sequence from pNL4.3-Urd was used as the template to generate the
Urd-GFP fusion protein. NTB-A was cloned by RT-PCR of mRNA obtained
from Jurkat cells as described (Ward et al., 2009). NTB-A primer pair sequence
is shown in Figure S3B. NTB-A D250–331 was constructed by site directed
mutagenesis (Stratagene) using the primer pair shown in Figure S3C. NTB-A
encoding retroviral constructs were generated by subcloning NTB-A into
pQCXIP (Clontech) bicistronic retroviral vector. Vpu-GFP and GFP encoding
retroviral constructs were generated by subcloning either Vpu-GFP or GFP
(from pACGFP-N1) into pQCXIP (Clontech). Retroviral particles were gener-
ated according to the manufacturer’s instructions (Clontech). The Vpu and
NTB-A coding regions of all plasmids were sequenced (University of Chicago
Sequencing Facility) to verify accuracy of the coding sequence.
Infections and transductions of primary cells were done as described in
Ward et al. (2009).
Transfection of HeLa Cells
HeLa-NTBA or HeLa-CD4 cells were seeded at a density of 1.25 3 105 cells/
well in a 6-well tissue culture plate (BD) and incubated overnight at 37C, 5%
CO2. Cells were transfected with 1.5 mg of Vpu expression plasmids using
HeLa Monster Trans-IT reagent (Mirus Bio) and incubated for 24–36 hr. For
inhibition of proteasome activity, proteasome inhibitors epoxomicin and
MG-132 (Sigma-Alrdrich) were reconstituted in DMSO (Mediatech) prior to
its addition to medium 24 hr after transfection. For inhibition of vesicle acidifi-
cation, bafilomycin A1 (Sigma-Aldrich) was reconstituted in DMSO (Medi-
atech) prior to its addition to medium 24 hr after transfection. Immunoblots
with mutant Vpu-GFP constructs were done in the absence of epoxomicin.
All HeLa cells were harvested with 0.05% trypsin (Mediatech) prior to analysis
by flow cytometry or immunoblots.
Endocytosis Assay
HeLa-NTB-A cells were transiently transfected with plasmids encoding either
GFP or Vpu-GFP for 24 hr. Cells were harvested with 0.05% trypsin and
labeled with monoclonal anti-human NTB-A (Biolegend). Cells were washed
with PBS, aliquoted into sterile tubes containing DMEM complete media,
and incubated at 37C with 5% CO2. At indicated times, cells were fixed
with 1% paraformaldehyde, washed with PBS, and labeled with APC conju-
gated goat anti-mouse IgG2 (Jackson Immunoresearch).
Immunoblots
For coimmunoprecipitation of Vpu and NTB-A, transfected HeLa and HeLa-
HA-NTB-A cells were harvested 48 hr posttransfection and lysed overnight
with 0.5% NP40 with 150 mM NaCl, 50 mM Tris-HCl, PMSF (Sigma) in meth-
anol and a protease inhibitor cocktail (Roche). Protein concentration was
determined by performing Bradford assay (Pierce). Cell lysates (200 mg)Microbe 8, 397–409, November 18, 2010 ª2010 Elsevier Inc. 407
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4C with rotation, and then incubated with anti-HA (Santa Cruz) at 4C over-
night with rotation. Precipitation was accomplished with protein G agarose
for 30 min at 4C. Immunoprecipitates and 20 mg of whole-cell lysates were
analyzed for the presence of Vpu on a 10% SDS-PAGE gel using a Mini
Protean 3 Cell (Bio-Rad) for 2 hr at 100 V and 500 mA in 13 SDS (Fisher Scien-
tific) running buffer. The gel was transferred to a methanol-soaked PVDF
membrane in Towbin transfer buffer for 2 hr at 250 Volts and 200 mA.
Membranes were blocked overnight at 4C in 5% skim milk (Fisher Scientific)
in Tris-buffered saline with 0.1% Tween 20 (Fisher Scientific) with agitation.
Membranes were probed with appropriate primary antibodies for 2 hr in 5%
milk solution followed by appropriate secondary antibodies for 1.5 hr in 5%
milk solution. Antibodies were detected by enzymatic chemiluminescence
using Pierce ECL western blotting substrate (Thermo) for 5 min on each
membrane. Membranes were then exposed to autoradiography film (Denville
Scientific) and developed in an autoprocessor (Konica).
Degranulation and Activation Assay
HIV-infected cells (106) were incubated with fresh PBMC(106) from the same
donor for 4 hr at 37C, 5%CO2. After the coincubation, cells were treated
with 1 mg/ml of human g-globulin to block Fc receptors and then stained
with fluorochrome-conjugated anti-CD3, CD14, CD20, CD56, CD107a, and
CD69 . Following surface staining, dead cells were selected using the LIVE/
DEAD Fixable Dead Cell Stain Kit (Invitrogen). Viable CD3CD20CD14
and CD56+ cells (2 3 104) were evaluated for the percentage of CD107a
and/or CD69.
To compare the ability of NK cells to degranulate when exposed to T cells
infected with VSV-G pseudotyped DHIV-3 expressing WT Vpu or URD, purified
NK cells left untreated or stimulated with 200 U/mL rhIL-2 were used and
stained as described above, except 2 3 105 infected cells were mixed with
105 NK cells. In addition, the cells were stained with anti-CD158a, CD158b,
and CD159a fluorochrome-conjugated antibodies (BDIS). All three Abs had
the same fluorochrome. Twenty-thousand viable CD3CD20CD14 and
CD56+ cells that possessed CD158a, CD158b, and/or CD159a or lacked all
three were evaluated for the percentage of CD107a surface expression.
NTB-A blocking was achieved by treating the NK cells with 5 mg/mL purified
anti-NTB-A (clone ON56) for 20min at 4C. All unbound antibody was removed
by washing once with RPMI complete. NK cells were then treated with 100 mg/
mL goat anti-mouse F(ab0)2 (Jackson Immuno) and incubated at 4C for 20min
prior to incubation with targets.
Redirected Degranulation Assay
Fresh PBMC (106) was exposed to 5 mg/ml purified anti-NKG2D and/or anti-
NTB-A . The PBMC were then mixed with P815 cells (105) and incubated for
4 hr at 37C, 5%CO2. After 4 hr the cells were stained as described above in
‘‘Degranulation and Activation Assay.’’ Ten-thousand viable CD3CD20
CD14 and CD56+ cells were evaluated for the percentage of CD107a.
Cytolytic Assay
Lysis of HIV-infected cells by NK cells was evaluated as described in detail in
Ward et al. (2007, 2009).
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